Overexpression of ECRG4 has been found to increase the sensitivity of gastric cancer cell line, SGC-7901 to 5-FU and NPC cell line, CNE1 to cisplatin, thereby improving the therapeutic effect of chemotherapy drugs (71, 72). Here, ECRG4 is linked to nasopharyngeal carcinoma.